25821 INDUSTRIAL BLVD., SUITE 100, HAYWARD, CA
Material disclosure
Stockholders Approve Amendment to 2021 Equity Incentive Plan
Reports First Quarter 2026 Financial Results
Appoints Melinda Lackey as General Counsel
Annual Report to Security Holders
Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model
Earnings Release
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
S-1
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Withdrawal of Offering Statement
Correspondence
Submission Upload
Deregistration Letter